Biorestorative Therapies (BRTX) revenue and earnings history
Biorestorative Therapies reported revenue of $360K for fiscal 2025 (year ended Dec 31, 2025), −10.3% on the year before, and net income of −$14.2M.
Revenue and net income, 17 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | $360K−10.3% | −$15.6M | −$14.2M | −$10.8M | $116K | −$10.9M | $3.33M | $0 | — | $1.51M | — | 10-K |
| 2024ended Dec 31, 2024 |
The latest quarter, insider trades and fund moves: Biorestorative Therapies (BRTX) on OQRO.
Common questions
What was Biorestorative Therapies's revenue in fiscal 2025?
$360K for the year ended Dec 31, 2025, as reported in its 10-K filed Mar 26, 2026. That is −10.3% on fiscal 2024 ($401K).
Has Biorestorative Therapies been profitable?
It reported a net loss in 17 of the years shown (2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025). The highest net income was −$1.2M in fiscal 2009.
What was Biorestorative Therapies's free cash flow in fiscal 2025?
Where these figures come from
The SEC’s companyfacts data: every figure Biorestorative Therapies tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.